Deerfield Management Company
Multi-Strategy- Manager
- Deerfield Management Company
- Quarter
- Q2 2026
- Filed
- 2026-08-14
- 13F value
- $9.59B
- Positions
- 82
- CIK
- 0001009258
| # | # Shares | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Nuvalent Inc670703107HISTORY | 22.22% | — | $2.13B | 17,248,450 | — | — | 13F |
| 2 | Brookdale SR Living Inc112463AF1NoteHISTORY | 6.11% | — | $0.59B | 306,885,000 | — | — | 13F |
| 3 | Revolution Medicines IncRVMDHISTORY | 4.67% | +4.1% | $0.45B | 2,392,000 | +95,000 | 1.12% | 13F |
| 4 | Praxis Precision Medicines IPRAXHISTORY | 3.36% | — | $0.32B | 963,351 | — | 3.45% | 13F |
| 5 | Viatris IncVTRSHISTORY | 3.35% | — | $0.32B | 20,206,170 | — | 1.76% | 13F |
| 6 | Centene Corp DelCNCHISTORY | 3.28% | (17.2%) | $0.31B | 4,901,000 | (1,016,091) | 0.99% | 13F |
| 7 | Revolution Medicines IncRVMDNoteHISTORY | 2.63% | NEW | $0.25B | 200,000,000 | +200,000,000 | — | 13F |
| 8 | United Therapeutics Corp DelUTHRHISTORY | 2.58% | — | $0.25B | 457,000 | — | 1.07% | 13F |
| 9 | Arrowhead Pharmaceuticals In04280AAC4NoteHISTORY | 2.51% | — | $0.24B | 200,000,000 | — | — | 13F |
| 10 | Legend Biotech CorpLEGNHISTORY | 2.45% | +5.9% | $0.24B | 8,137,638 | +450,000 | 2.20% | 13F |
| 11 | Cogent Biosciences IncCOGTHISTORY | 2.02% | (44.6%) | $0.19B | 5,006,104 | (4,037,799) | 2.88% | 13F |
| 12 | Genmab A/SGMABHISTORY | 1.97% | +178.8% | $0.19B | 6,865,000 | +4,403,000 | — | 13F |
| 13 | Brookdale SR Living IncBKDHISTORY | 1.95% | — | $0.19B | 11,637,032 | — | 4.87% | 13F |
| 14 | Vera Therapeutics IncVERAHISTORY | 1.75% | +5.2% | $0.17B | 3,916,400 | +194,300 | 5.43% | 13F |
| 15 | Ionis Pharmaceuticals IncIONSHISTORY | 1.64% | — | $0.16B | 1,979,669 | — | 1.19% | 13F |
| 16 | Celcuity IncCELCHISTORY | 1.58% | (15.3%) | $0.15B | 1,451,014 | (262,986) | 2.97% | 13F |
| 17 | Biocryst Pharmaceuticals IncBCRXHISTORY | 1.57% | +0.4% | $0.15B | 15,096,403 | +58,403 | 5.91% | 13F |
| 18 | Newamsterdam Pharma CompanyNAMSHISTORY | 1.51% | — | $0.14B | 4,264,789 | — | 3.57% | 13F |
| 19 | Acadia Healthcare Company InACHCHISTORY | 1.39% | — | $0.13B | 4,520,000 | — | — | 13F |
| 20 | Tango Therapeutics IncTNGXHISTORY | 1.37% | +1.1% | $0.13B | 4,190,611 | +43,798 | 2.49% | 13F |
| 21 | Adapthealth CorpAHCOHISTORY | 1.25% | — | $0.12B | 11,477,730 | — | 8.42% | 13F |
| 22 | Pharvaris N VPHVSHISTORY | 1.22% | +8.0% | $0.12B | 3,376,042 | +250,000 | 5.18% | 13F |
| 23 | Celcuity IncCELCNoteHISTORY | 1.19% | NEW | $0.11B | 100,000,000 | +100,000,000 | — | 13F |
| 24 | Arrowhead Pharmaceuticals InARWRHISTORY | 1.18% | (11.7%) | $0.11B | 1,389,055 | (184,242) | 0.98% | 13F |
| 25 | Dianthus Therapeutics IncDNTHHISTORY | 1.14% | +10.3% | $0.11B | 1,125,313 | +105,500 | 2.01% | 13F |
| 26 | Larimar Therapeutics IncLRMRHISTORY | 1.13% | — | $0.11B | 35,606,974 | — | 34.28% | 13F |
| 27 | Mineralys Therapeutics IncMLYSHISTORY | 1.11% | NEW | $0.11B | 3,958,000 | +3,958,000 | 4.48% | 13F |
| 28 | Alignment Healthcare IncALHCNoteHISTORY | 1.08% | — | $0.10B | 61,000,000 | — | — | 13F |
| 29 | Ideaya Biosciences IncIDYAHISTORY | 1.06% | +77.4% | $0.10B | 2,714,503 | +1,184,495 | 2.81% | 13F |
| 30 | Xenon Pharmaceuticals IncXENEHISTORY | 1.02% | — | $0.10B | 1,615,696 | — | 1.67% | 13F |
| 31 | Ionis Pharmaceuticals IncIONSNoteHISTORY | 0.97% | — | $0.09B | 60,000,000 | — | — | 13F |
| 32 | Savara IncSVRAHISTORY | 0.87% | — | $0.08B | 13,569,000 | — | 6.60% | 13F |
| 33 | Lantheus Hldgs IncLNTHHISTORY | 0.87% | (9.1%) | $0.08B | 752,999 | (75,000) | 1.15% | 13F |
| 34 | Syndax Pharmaceuticals IncSNDXHISTORY | 0.86% | — | $0.08B | 3,779,900 | — | 4.23% | 13F |
| 35 | Zenas Biopharma IncZBIONoteHISTORY | 0.84% | +3.4% | $0.08B | 67,200,000 | +2,200,000 | — | 13F |
| 36 | Biomarin Pharmaceutical IncBMRNHISTORY | 0.80% | +56.5% | $0.08B | 1,332,836 | +481,280 | 0.69% | 13F |
| 37 | Pfizer IncPFEHISTORY | 0.76% | — | $0.07B | 3,040,000 | — | 0.05% | 13F |
| 38 | Indivior Pharmaceuticals IncINDVHISTORY | 0.71% | (46.8%) | $0.07B | 1,648,895 | (1,448,895) | 1.40% | 13F |
| 39 | Bio Rad Labs IncBIOHISTORY | 0.69% | — | $0.07B | 226,070 | — | 0.82% | 13F |
| 40 | Ars Pharmaceuticals IncSPRYHISTORY | 0.63% | — | $0.06B | 7,503,812 | — | 7.55% | 13F |
| 41 | Stoke Therapeutics IncSTOKHISTORY | 0.62% | — | $0.06B | 1,823,500 | — | 2.83% | 13F |
| 42 | Structure Therapeutics IncGPCRHISTORY | 0.61% | +41.4% | $0.06B | 1,086,000 | +318,007 | 0.51% | 13F |
| 43 | Envista Holdings CorporationNVSTHISTORY | 0.61% | — | $0.06B | 2,210,100 | — | 1.38% | 13F |
| 44 | Inspire Med Sys IncINSPHISTORY | 0.60% | (52.0%) | $0.06B | 1,296,862 | (1,406,376) | 4.49% | 13F |
| 45 | Caredx IncCDNAHISTORY | 0.59% | (8.8%) | $0.06B | 1,997,618 | (193,382) | 3.86% | 13F |
| 46 | Boston Scientific CorpBSXHISTORY | 0.59% | NEW | $0.06B | 1,315,000 | +1,315,000 | 0.09% | 13F |
| 47 | Belite Bio IncBLTEHISTORY | 0.57% | +17.5% | $0.06B | 357,199 | +53,186 | 0.91% | 13F |
| 48 | Parabilis Medicines IncPBLSHISTORY | 0.54% | NEW | $0.05B | 1,880,704 | +1,880,704 | 12.09% | 13F |
| 49 | Certara IncCERTHISTORY | 0.51% | (3.8%) | $0.05B | 7,512,928 | (295,677) | 4.93% | 13F |
| 50 | Disc Medicine IncIRONHISTORY | 0.50% | — | $0.05B | 657,000 | — | 1.71% | 13F |
| 51 | Livanova PLCLIVNNoteHISTORY | 0.48% | — | $0.05B | 34,280,000 | — | — | 13F |
| 52 | Bridgebio Oncology TherapeutBBOTHISTORY | 0.39% | — | $0.04B | 4,885,446 | — | 6.09% | 13F |
| 53 | Tyra Biosciences IncTYRAHISTORY | 0.34% | +85.2% | $0.03B | 1,017,000 | +468,000 | 1.70% | 13F |
| 54 | Monopar Therapeutics IncMNPRHISTORY | 0.31% | — | $0.03B | 323,745 | — | 4.82% | 13F |
| 55 | Sionna Therapeutics IncSIONHISTORY | 0.31% | (29.8%) | $0.03B | 680,916 | (289,674) | 1.51% | 13F |
| 56 | Immunocore Hldgs PLCIMCRNoteHISTORY | 0.28% | — | $0.03B | 30,000,000 | — | — | 13F |
| 57 | Avalyn Pharmaceuticals IncAVLNHISTORY | 0.25% | NEW | $0.02B | 731,000 | +731,000 | 1.65% | 13F |
| 58 | Foghorn Therapeutics IncFHTXHISTORY | 0.22% | — | $0.02B | 4,394,367 | — | 7.40% | 13F |
| 59 | Beta Bionics IncBBNXHISTORY | 0.22% | — | $0.02B | 1,324,000 | — | 2.94% | 13F |
| 60 | Alnylam Pharmaceuticals IncALNYHISTORY | 0.21% | — | $0.02B | 67,935 | — | 0.05% | 13F |
| 61 | Bright Minds Biosciences IncDRUGHISTORY | 0.21% | — | $0.02B | 283,000 | — | 6.26% | 13F |
| 62 | Odyssey Therapeutics IncODTXHISTORY | 0.20% | NEW | $0.02B | 1,046,139 | +1,046,139 | 2.18% | 13F |
| 63 | The Oncology Institute IncSTLNHISTORY | 0.19% | — | $0.02B | 3,360,052 | — | — | 13F |
| 64 | Kyverna Therapeutics IncKYTXHISTORY | 0.19% | — | $0.02B | 2,000,000 | — | 3.23% | 13F |
| 65 | Alamar Biosciences IncALMRHISTORY | 0.17% | NEW | $0.02B | 600,000 | +600,000 | 0.86% | 13F |
| 66 | Chemed Corp NewCHEHISTORY | 0.15% | NEW | $0.01B | 30,000 | +30,000 | 0.23% | 13F |
| 67 | Spyglass Pharma IncSGPHISTORY | 0.13% | — | $0.01B | 550,000 | — | 1.64% | 13F |
| 68 | Neogenomics IncNEONoteHISTORY | 0.13% | (82.1%) | $0.01B | 13,040,000 | (59,649,000) | — | 13F |
| 69 | Adagene IncADAGHISTORY | 0.12% | NEW | $0.01B | 2,666,666 | +2,666,666 | 4.50% | 13F |
| 70 | Hemab Therapeutics Hldgs IncCOAGHISTORY | 0.11% | NEW | $0.01B | 275,000 | +275,000 | 0.59% | 13F |
| 71 | Mobia Med IncMOBIHISTORY | 0.09% | NEW | $0.01B | 670,752 | +670,752 | 2.01% | 13F |
| 72 | Embecta CorpEMBCHISTORY | 0.09% | — | $0.01B | 2,534,961 | — | 4.47% | 13F |
| 73 | Veracyte IncVCYTHISTORY | 0.06% | (86.1%) | $0.01B | 101,000 | (625,000) | 0.13% | 13F |
| 74 | Annexon IncANNXHISTORY | 0.03% | — | $<0.01B | 583,913 | — | 1.51% | 13F |
| 75 | Alector IncALECHISTORY | 0.02% | — | $<0.01B | 1,055,192 | — | 0.95% | 13F |
| 76 | Newamsterdam Pharma CompanyNAMSWHISTORY | 0.02% | — | $<0.01B | 92,787 | — | 0.08% | 13F |
| 77 | Edwards Lifesciences CorpEWHISTORY | 0.01% | — | $<0.01B | 13,702 | — | 0.00% | 13F |
| 78 | Mirum Pharmaceuticals IncMIRMHISTORY | 0.01% | NEW | $<0.01B | 6,027 | +6,027 | 0.01% | 13F |
| 79 | Humana IncHUMHISTORY | <0.01% | — | $<0.01B | 917 | — | — | 13F |
| 80 | The Oncology Institute IncSTLNWHISTORY | <0.01% | — | $<0.01B | 1,250,000 | — | — | 13F |
| 81 | PMV Pharmaceuticals IncPMVPHISTORY | <0.01% | — | $<0.01B | 8,790 | — | 0.02% | 13F |
| 82 | Surrozen IncSRZNHISTORY | <0.01% | — | $<0.01B | 166,666 | — | 1.42% | 13F |
Positions are from the latest 13F-HR (period end 2026-06-30). Weights are calculated: position value ÷ the 13F book. Schedule 13D/13G stakes are merged in when present (shares and percent of class, no dollar value). Chg Shares and % Chg compare with the adjacent prior quarter's 13F only. % Out is either calculated (position shares ÷ issuer shares outstanding from the issuer's XBRL cover page; weighted-average basic shares as a fallback) or reported (percent of class on a Schedule 13D/13G newer than the 13F period) — hover a value for its source and date. Unavailable figures show “—”, never an estimate. Methodology